In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer expands MIT genome collaboration

This article was originally published in Scrip

Executive Summary

Bayer and the Broad Institute of MIT and Harvard are hoping to create new cardiovascular treatments and diagnostics by expanding their collaboration in genomic research, which is currently focused on oncology. The collaboration combines Bayer's expertise in cardiology and the institute's genomics and biology knowhow. The two organizations will focus on genetic discovery, target validation, and drug discovery. A joint steering committee will oversee the collaboration and a joint research committee will supervise research progress and direction. Financial terms of the agreement have not been disclosed. Cardiovascular genomics is an emerging field of cardiology that uses genomic information to characterize disease risk and identify new therapeutic targets for drug discovery. Back in 2013 Bayer and the institute struck a five-year collaboration in oncogenomics and drug discovery.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts